Vera Therapeutics (VERA) Says TRUTAKNA Met All Phase III IgA Nephropathy Endpoints

• Vera Therapeutics (NasdaqGM:VERA) reported that TRUTAKNA met all prespecified endpoints in the final phase III ORIGIN 3 IgA nephropathy trial.
• The company plans to submit a supplemental Biologics License Application seeking full FDA approval for TRUTAKNA by the end of the year.
• TRUTAKNA stabilized kidney function, reduced IgA nephropathy disease progression and showed a favorable safety profile compared with placebo in ORIGIN 3.
• The successful ORIGIN 3 readout and planned supplemental BLA filing for TRUTAKNA deserve to be weighed against our broader findings on Vera. We have also spotted 1 major warning sign worth knowing about at Vera Therapeutics.

For readers looking beyond Vera Therapeutics and into similar treatment themes, the next logical stop is 39 healthcare AI stocks.

Vera Therapeutics is a US biotech focused on treatments for immunological diseases, so progress in IgA nephropathy directly reflects how its drug pipeline lines up with that mission. With a market value of about $2.5b, it sits firmly in the clinical stage camp, where individual trial outcomes can materially shape the development story.

2 things going right for Vera Therapeutics that this headline doesn't cover.

TRUTAKNA data backs Vera Therapeutics’ IgAN thesis but raises the bar for execution

For investors, this ORIGIN 3 readout gives Vera Therapeutics hard kidney function data to support the key catalyst already in motion, the supplemental BLA for TRUTAKNA. eGFR stabilization and a 76% reduction in composite kidney disease progression events directly support the case that Vera is targeting disease modification in IgA nephropathy, not just proteinuria reduction. That strengthens the core product story and helps underpin the existing commercial push, but it also increases pressure on Vera to convert early interest, such as the more than 350 patient start forms, into sustained prescriptions in a market where other IgAN treatments are also competing for share.

The clearest checkpoint from here is the fourth quarter 2026 supplemental BLA submission and the FDA’s acceptance of that filing. Alongside that regulatory step, investors can track TRUTAKNA uptake through disclosed prescription trends or updated patient start numbers, which will show whether the clinical data is translating into a durable revenue base for the business.

Add Vera Therapeutics to your Watchlist and get alerts as these catalysts play out.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com